^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    5d
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Nebraska | Trial completion date: Mar 2027 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    temozolomide • abexinostat (CG-781)
    9d
    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA (clinicaltrials.gov)
    P2, N=37, Recruiting, Northwell Health | Trial completion date: May 2027 --> May 2036 | Trial primary completion date: May 2026 --> May 2035
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    Erbitux (cetuximab)
    10d
    Predicting Clinical Prognosis and Treatment Response in Glioblastoma Based on Gene Replication Stress-Related Features. (PubMed, Curr Med Chem)
    We constructed and verified a four-gene ORS-based prognosis model for GBM, linking replication stress to immune evasion and drug sensitivity for the first time. Experimental validation confirmed the pro-tumorigenic role of PDCL3, offering potential biomarkers and therapeutic targets.
    Journal • IO biomarker
    |
    NXPH4 (Neurexophilin 4)
    |
    Xalkori (crizotinib) • vinorelbine tartrate
    14d
    Forsythoside A Alleviates Neuroinflammatory Damage via Inhibiting TLR4/NF-κB/NLRP3 Activation-Induced Astrocyte Pyroptosis in Cerebral Ischemia-Reperfusion. (PubMed, CNS Neurosci Ther)
    FA alleviates neuroinflammatory damage through inhibiting the TLR4/NF-κB axis and blocking NLRP3 inflammasome-induced astrocyte pyroptosis.
    Journal • IO biomarker
    |
    TLR4 (Toll Like Receptor 4) • NLRP3 (NLR Family Pyrin Domain Containing 3) • RELA (RELA Proto-Oncogene)
    14d
    GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Mayo Clinic | Suspended --> Recruiting
    Enrollment open
    |
    IDH wild-type
    |
    Keytruda (pembrolizumab)
    20d
    Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    22d
    MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features. (PubMed, J Pathol Clin Res)
    ZM fusion was associated with a worse prognosis in both astrocytoma (OS p < 0.001, PFS p < 0.001) and glioblastoma (OS, p = 0.252; PFS, p = 0.010) patients. We highlight the utmost relevance of ZM fusion as an adverse prognostic factor in astrocytoma (11/382, 2.88%) and glioblastoma grade 4 (11/401, 2.74%) patients and suggest that the grading of these tumors should be refined.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    MET expression
    |
    TruSight Tumor 170 Assay
    23d
    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov)
    P1/2, N=62, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    25d
    Expanding the molecular grading criteria in IDH-mutant astrocytoma. (PubMed, Neuro Oncol)
    The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CCND2 (Cyclin D2)
    |
    EGFR mutation • PIK3CA mutation • EGFR amplification • CDKN2A deletion • MYCN amplification • PDGFRA mutation
    29d
    RagC and Map4K3 deficiency in high-grade gliomas drives proliferation and modulates mTORC1-dependent cellular functions. (PubMed, J Neuropathol Exp Neurol)
    In contrast, RagC-deficient U87 cells showed increased senescence but no autophagy induction. These data show that losses of RagC and Map4K3 in malignant gliomas have proliferation-inducing effects and differentially modulate key mTOR signaling-dependent cellular mechanisms.
    Journal
    |
    TFEB (Transcription Factor EB 2) • RRAGD (Ras related GTP binding)
    1m
    Clinical and genetic determinants of glioblastoma survival: a retrospective study. (PubMed, Front Mol Neurosci)
    A significant finding was the strong association between extent of resection, tumor proximity to the ventricular system and survival: patients with tumors closer to the ventricles had significantly shorter survival, highlighting the critical role of spatial tumor characteristics in glioblastoma outcomes. These results suggest that integrating clinical, genetic and spatial tumor data into personalized treatment approaches could improve prognosis.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    TP53 mutation • EGFR mutation
    1m
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Mayo Clinic
    New P1/2 trial
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)